Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study

Cancer

Volumn 118, Issue 15, 2012, Pages 3793-3800

  Wang, Haijun ^a   Chen, Yiming ^b   Li, Fanglin ^c   Delasalle, Kay ^b   Wang, Jialei ^d   Alexanian, Raymond ^b   Kwak, Larry ^b   Rustveld, Luis ^a   Du, Xianglin L ^e   Wang, Michael ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SHANDONG UNIVERSITY   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

epidemiology; incidence; SEER data; trends; Waldenstrom macroglobulinemia

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; BIOSTATISTICS; CAUCASIAN; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; WALDENSTROEM MACROGLOBULINEMIA;

AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; REGISTRIES; SEER PROGRAM; UNITED STATES; WALDENSTROM MACROGLOBULINEMIA;

EID: 84859882662     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26627     Document Type: Article

References (29)

1. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009; 27: 120-126.
2. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003; 30: 110-115.
3. Bjorkholm M,. Lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia In:, Canellos G, Lister A, Young B, eds. The Lymphomas. Philadelphia, PA: Saunders; 2006: 374-380.
4. Waldenstrom J., Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia-a new syndrome? Acta Med Scand. 1944; 117: 216-217.
5. Neparidze N, Dhodapkar MV,. Waldenstrom's macroglobulinemia: recent advances in biology and therapy. Clin Adv Hematol Oncol. 2009; 7: 677-681, 687-690.
6. Owen RG,. Developing diagnostic criteria in Waldenstrom's macroglobulinemia. Semin Oncol. 2003; 30: 196-200.
7. Vijay A, Gertz MA,. Waldenstrom macroglobulinemia. Blood. 2007; 109: 5096-5103.
8. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M,. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000; 18: 214-226.
9. Ioachim HL, Medeiros LJ,. Ioachim's lymph node pathology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
10. Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr,. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998; 82: 1078-1081.
11. Herrinton LJ, Weiss NS,. Incidence of Waldenstrom's macroglobulinemia. Blood. 1993; 82: 3148-3150.
12. Ries LG, Pollack ES, Young JL Jr,. Cancer patient survival: Surveillance, Epidemiology, and End Results Program, 1973-79. J Natl Cancer Inst. 1983; 70: 693-707.
13. Groves FD, Linet MS, Travis LB, Devesa SS,. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000; 92: 1240-1251.
14. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007; 110: 695-708.
15. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Registries Research Data (1973-2007). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Released April 2010, based on the November 2009 submission. Available at: Accessed on August 31, 2011.
16. Phekoo KJ, Jack RH, Davies E, Moller H, Schey SA,. The incidence and survival of Waldenstrom's macroglobulinaemia in South East England. Leuk Res. 2008; 32: 55-59.
17. Linet MS, Humphrey RL, Mehl ES, et al. A case-control and family study of Waldenstrom's macroglobulinemia. Leukemia. 1993; 7: 1363-1369.
18. Treon SP, Hatjiharissi E, Leleu X, et al. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2007; 7 (suppl 5): S199-S206.
19. Knudson AG,. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001; 1: 157-162.
20. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS,. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107: 265-276.
21. Boren E, Gershwin ME,. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev. 2004; 3: 401-406.
22. Coussens LM, Werb Z,. Inflammation and cancer. Nature. 2002; 420: 860-867.
23. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004; 101: 3-27.
24. Rose PG,. Re: annual report to the nation on the status of cancer (1973 through 1998), featuring cancer with recent increasing trends. J Natl Cancer Inst. 2001; 93: 1656.
25. Levi F, Lucchini F, Negri E, La Vecchia C,. Trends in mortality from non-Hodgkin's lymphomas. Leuk Res. 2002; 26: 903-908.
26. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C,. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Cancer. 2004; 110: 155-169.
27. Schuster SR, Rajkumar SV, Dispenzieri A, et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol. 2010; 85: 853-855.
28. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF,. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002; 94: 1537-1545.
29. Turner JJ, Hughes AM, Kricker A, et al. WHO non-Hodgkin's lymphoma classification by criterion-based report review followed by targeted pathology review: an effective strategy for epidemiology studies. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2213.